Join us on the 2nd November at Hinxton Hall for an exploration of the ‘connected person’ and their connected environment

Bridging communities to improve dementia outcomes

Brought to you by CW (Cambridge Wireless)

A collaborative event by Eastern AHSN, Cambridge Wireless and One Nucleus

Registration for this event is now closed.

About the event

With the current ageing population, dementia is becoming more prevalent and it is estimated that by 2025, around a million people in the UK will have dementia. Now is the time to coordinate how we maximise outcomes for patients, carers, health and social care systems to better identify at risk individuals to help delay onset and impact of disease, manage symptoms, discover and develop new treatments and help patients maintain their independence.

The One Nucleus, Cambridge Wireless and Eastern AHSN meeting will bring together presentations from innovative approaches spanning diagnostics, drug development, medtech and digital technologies to apply to the multidisciplinary prevention and care of dementia patients.

It should appeal to anyone within these sectors with an interest in dementia research or enthusiasts of cross sector collaboration to solve national healthcare challenges.

Calling all innovators and research groups

The meeting will include an opportunity for up to six companies or research groups to pitch their innovative solution in the space of Dementia. If you would like to apply for a pitching slot, please email,

Calling potential sponsors

We are offering limited sponsoring opportunities to organisations/companies who would like to raise their profile at the meeting. Please email,

Dementia joint

The Eastern Academic Health Science Network (Eastern AHSN) is one of 15 Academic Health Science Networks (AHSNs) set up and funded by NHS England to spread innovation at pace and scale to improve health and generate economic growth.

The Eastern AHSN works as a unique and trusted connector, broker and change agent to bring together the NHS, clinical and industry innovators, researchers and academics, local government and the third sector.  Focusing on the unmet health needs of people in the eastern region, we work in partnership to identify, co-develop, adopt and spread new proven technology and transform services to improve health outcomes for all.   

Cambridge Wireless (CW) is the leading international community for companies involved in the research, development and application of wireless and mobile, internet, semiconductor and software technologies. With over 400 members from major network operators and device manufacturers to innovative start-ups and universities, CW stimulates debate and collaboration, harnesses and shares knowledge, and helps to build connections between academia and industry. CW's 19 Special Interest Groups (SIGs) provide its members with a dynamic forum where they can network with their peers, track the latest technology trends and business developments and position their organisations in key market sectors. CW also organises major conferences and start-up competitions along with other high-quality industry networking events and dinners. With headquarters at the heart of Cambridge, UK, CW partners with other international industry clusters and organisations to extend its reach and remain at the forefront of global developments and business opportunities.

One Nucleus is an award winning not-for-profit life sciences and healthcare membership organisation centred on the Greater London-Cambridge-East of England corridor. Headquartered in Cambridge, at the heart of Europe’s largest life sciences and healthcare cluster, we support those institutions, companies and individuals undertaking activity in or with the above region. 

Through providing the local, UK-wide and international connectivity, One Nucleus seeks to enable their members to maximise their performance.  In an increasingly outsourced, collaborative and multi-disciplinary sector, bringing the best people together is key to translating great innovation into great products that markedly improve patient outcomes and drive economic development.

You can follow @CambWireless on Twitter.

Hosted by Central Working

The UK’s premier homegrown shared work space provider, transforming the way people work and companies grow.

View profile


Expand all

The information supplied below may be subject to change before the event.


Registration with refreshments


Welcome from the hosts


Clinical and patient context

Professor James Rowe, Director, Cambridge Centre for Frontotemporal Dementia and Related Disorders


Bringing Academia and Industry together to overcome drug discovery challenges

Dr Carol Routledge. Director of Research, Alzheimer's Research UK


Innovation in Therapeutic Approach

Dr Declan Jones, Vice President of Neuroscience Scientific Innovation, Johnson & Johnson Innovation


Neuroplasticity Based Technology for Dementia

Kartheka Bojan, CEO, Cerebrum Matter Ltd


Linking therapeutics, device and digital technology for personalised care

Dr Hakim Yadi, Chief Executive Officer & Co-Founder, Closed Loop Medicine


Pitch session

This session will give the opportunity to up to 6 companies or research groups to pitch their innovative solution in the space of Dementia. If you would like to apply for a pitching slot please email


Closing remarks


Drinks and networking




Kartheka Bojan - CEO, Cerebrum Matter

Miss Kartheka Bojan, Founder & CEO of Cerebrum Matter Ltd, a digital healthcare start-up working on early dementia. She holds an MSc in Biomedical Engineering from the University of Nottingham. After working at IBM India, she spent 5 years in the UK developing medical devices.

In her role as Chief Medical Engineer at her previous employment, she designed a Nanotechnology-based Non-Invasive Continuous Glucose Monitoring Device. She is the author of pending patents in EEG technology for Alzheimer’s & a Glucose Monitoring device and has also published work on Design of Biosensors with Gold Nanoparticles.

Her innovative technical and business skills have been recognized with awards from NASA, IEEE and Nottingham &amp Leicester Universities. The idea of creating Cerebrum Matter stems from her personal experience of accompanying her grandmother through a rough journey with Parkinson’s, a decade ago.

Bojan’s vision to treat early onset dementia through digital therapy has been transformed into Cerebrum Matter’s mission to reduce the prevalence of disabling symptoms for people living with dementia.

Declan Jones - Vice President of Neuroscience Scientific Innovation, Johnson & Johnson Innovation

Declan is Vice President of Neuroscience Scientific Innovation at Johnson & Johnson Innovation. In this role, Declan uses his drug discovery and scientific experience to identify and advance external opportunities in the areas of Alzheimer’s Disease and Mood Disorders.


Declan previously worked for GSK’s Centre of Excellence for External Drug Discovery (CEEDD) as Head of Research.  He was responsible for creating scientific strategies, identifying external opportunities, and managing programs from preclinical to Phase II programs across all therapeutic areas.


Prior to GSK’s CEEDD, he spent 14 years in GSK’s neuroscience R&D, finishing as Head of In Vivo Neurobiology and Strategy Leader for schizophrenia and bipolar disorders within the Psychiatry Centre of Excellence for Drug Discovery. Declan was the recipient of an R&D Pipeline award for his leadership of a schizophrenia program with a successful Phase II outcome.


Declan received his PhD from the University of Bradford and did post-doctoral work at Emory University and University of Hertfordshire before joining the pharmaceutical industry.  He is currently an Executive Team member for the Dementias Platform UK (DPUK) and the Wellcome Trust Neuroinflammation Consortium, and is a SAB member for the UK Dept of Health (PM’s Dementia Challenge) and the South London and Maudsely NHS Foundation Trust Biomedical Research Centre at the Institute of Psychiatry, Psychology, and Neuroscience (King’s College London), and works closely with the Dementia Discovery Fund.

Carol Routledge - Director of Research, Alzheimer’s Research UK

Dr Carol Routledge is the Director of Research at Alzheimer’s Research UK where she currently drives the research agenda.

Carol moved to the charity in 2017 from the Dementia Discovery Fund, where she was a Venture Partner with a key focus on identifying and developing novel disease-modifying mechanisms for the treatment of all types of dementia, sourcing opportunities from academic research groups and small companies.

She has had a successful career with a number of UK and US based major pharmaceutical and biotechnology companies, with leadership roles in drug acquisition and translational medicine strategies, with a focus on neuroscience.

A combination of preclinical and clinical experience gives her the advantage of being able to apply a strong scientific rationale and innovative experimental approaches to clinical development.

Carol has a PhD in neuropharmacology from Queens Medical School in Nottingham.

James Rowe - Professor, Cambridge Centre for Frontotemporal Dementia and Related Disorders

Professor James B. Rowe is both a neuroscientist and a cognitive neurologist. His early training in Medical Sciences and Experimental Psychology (1st class hons.) began at Downing College at the University of Cambridge (1988-1991), followed by Magdalen College at the University of Oxford (1991-1994) and a PhD at the Functional Imaging Laboratory of the Wellcome Department of Cognitive Neurology (1998-2001), supervised by Professor Richard Frackowiak and Professor Dick Passingham. His PhD focused on the neural mechanisms of response selection and attention to action, in health and Parkinson’s disease, using human neuroimaging techniques, such as positron emission tomography, functional magnetic resonance imaging (fMRI), and repetitive transcranial magnetic stimulation (TMS). After completing his PhD he undertook full time clinical specialist training in neurology, for four years. During his clinical training he continued research, including UK and international collaborations on the interactions within cortical and subcortical neural networks. His Wellcome Trust Intermediate Research Fellowship (2005-2009) enabled him to develop further research methodologies (including magnetoencephalography), clinical experience with Frontotemporal dementia, and the theoretical foundations of his later research program. In 2009, he became a Wellcome Trust Senior Research Fellow in Clinical Science. In 2015, he was appointed as the Professor of Cognitive Neurology at the University of Cambridge and an affiliated Professor of Clinical Neuroscience at the University of Copenhagen in Denmark. His scientific work has been published in more than 200 high-ranking peer-reviewed articles including Science, Brain, Nature Communications, and Neurology. He is an active consultant neurologist, leading regional specialist clinics for patients with early dementia, frontotemporal dementia, Progressive Supranuclear Palsy, and other ‘tauopathies’, and he is a consultant in the Cambridge Memory Clinic.

Hakim Yadi OBE - Chief Executive Officer & Co-Founder, Closed Loop Medicine

Hakim is a Co-Founder and chief executive of Closed Loop Medicine. He joined CLM from the Northern Health Science Alliance Ltd, the pan-Northern health partnership which brought together for the first time 20 research-based NHS hospitals, the North’s Academic Health Science Networks and Universities to collaborate on improving health outcomes across the North.

As the founding CEO of the NHSA, Hakim was instrumental in raising the profile of the region in parliament, with investors and the media to help focus resources on improving healthcare services for the 15 million population living in the North and its eight great cities. Central to the NHSA’s mission was to raise awareness of the region’s high mortality rates and to seek national solutions to improve these morbidity levels by working with all local agencies to improve health - and therefore wealth and well-being -outcomes.

Hakim was also highly successful in working with companies in the North to attract substantial domestic and overseas investment into the region’s life science sector, one of the most vibrant in the country.

Having worked with specialist drug and digital companies all around the world, he has a deep understanding of innovation systems integration.

Hakim started his career at PA Consulting, where he co-managed the company's translational medicine team. During his time at PA, he was seconded to the UK Government where he worked as the Chief Operations Officer and was a founding member of the UK Department of International Trade (DIT) Life Sciences Organisation (LSO).

He holds a PhD from the University of Cambridge and in 2017 he was awarded an OBE for services to Healthcare Technology and the Economy.

Event Location

Open in google maps

Location info

The Bradfield Centre, 184 Cambridge Science Park Milton Road, Cambridge, CB4 0GA

Related events

  • CW (Cambridge Wireless)

    A review of LoRaWAN

    Register now
  • CW (Cambridge Wireless)

    Changemakers Seed Fund Showcase Day

    Register now
  • CW (Cambridge Wireless)

    Making Smart Devices Smarter!

    Register now

Subscribe to the CW newsletter

This site uses cookies.

We use cookies to help us to improve our site and they enable us to deliver the best possible service and customer experience. By clicking accept or continuing to use this site you are agreeing to our cookies policy. Learn more

Reserve your place

Join the CW network

CW is a leading and vibrant community with a rapidly expanding network of nearly 400 companies across the globe interested in the development and application of wireless and mobile technologies to solve business problems.

Sign in to your account

Please sign in to your CW account to reserve a place at this event and to qualify for any member discounts.

Start typing and press enter or the magnifying glass to search

Sign up to our newsletter
Stay in touch with CW

Choosing to join an existing organisation means that you'll need to be approved before your registration is complete. You'll be notified by email when your request has been accepted.

Your password must be at least 8 characters long and contain at least 1 uppercase character, 1 lowercase character and at least 1 number.

I would like to subscribe to

Select at least one option*